Put New Aimovig for Migraine Prophylaxis Into Perspective

October 2018

You'll hear buzz about Aimovig (AIM-oh-vig, erenumab), a new biologic to PREVENT migraines in adults.

It will be the first drug that blocks receptors for calcitonin gene-related peptide (CGRP)...a vasodilator and pain sensitizer that spikes during migraine attacks.

Aimovig may provide one or two fewer migraine days per month versus placebo. This seems similar to first-line oral meds for migraine prophylaxis...such as beta-blockers, topiramate, or valproate.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Influenza Emphasize Influenza Immunization for 2018-19
Epinephrine Be Ready for Questions About EpiPen Shortages and Auvi-Q
Diabetes Know Where Basal Insulin Combo Products Fit In to Diabetes Management
Cardiology Address Depression in Patients After a Heart Attack
Migraine Put New Aimovig for Migraine Prophylaxis Into Perspective
Pharmacogenetics Put Pharmacogenetic Testing for Mental Health Meds Into Perspective
Dermatology Help Get to the Bottom of Diaper Rash
Pregnancy Weigh the Risks and Benefits to Decipher Med Safety in Pregnancy
Natural Medicines Focus on Safety if Patients Use Essential Oils
HIV & AIDS Expect Integrase Inhibitors to Gain an Edge in Treating HIV
Antithrombotics Consider Lower Doses of Oral Anticoagulation With Aspirin Plus Clopidogrel
Practice Remember "Cooler Heads Prevail" When Conflict Arises

Put New Aimovig for Migraine Prophylaxis Into Perspective

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents